These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38114357)

  • 1. Efficacy of Mobocertinib and Amivantamab in Patients With Advanced Non-Small Cell Lung Cancer With EGFR Exon 20 Insertions Previously Treated With Platinum-Based Chemotherapy: An Indirect Treatment Comparison.
    Ou SI; Prawitz T; Lin HM; Hong JL; Tan M; Proskorovsky I; Hernandez L; Jin S; Zhang P; Lin J; Patel J; Nguyen D; Neal JW
    Clin Lung Cancer; 2024 May; 25(3):e145-e152.e3. PubMed ID: 38114357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Matching-adjusted indirect comparison of amivantamab vs mobocertinib in platinum-pretreated
    Kim TM; Girard N; Leighl NB; Sabari J; Rahhali N; Schioppa CA; Diels J; Sermon J; Chandler C; Kapetanakis V; Jain R; Li T; Sanden SV
    Future Oncol; 2024 Mar; 20(8):447-458. PubMed ID: 37882460
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations: An indirect comparison.
    Ou SI; Lin HM; Hong JL; Yin Y; Jin S; Lin J; Mehta M; Zhang P; Nguyen D; Neal JW
    Lung Cancer; 2023 May; 179():107186. PubMed ID: 37075617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations.
    Chouaid C; Bosquet L; Girard N; Kron A; Scheffler M; Griesinger F; Sebastian M; Trigo J; Viteri S; Knott C; Rodrigues B; Rahhali N; Cabrieto J; Diels J; Perualila NJ; Schioppa CA; Sermon J; Toueg R; Erdmann N; Mielke J; Nematian-Samani M; Martin-Fernandez C; Pfaira I; Li T; Mahadevia P; Wolf J
    Adv Ther; 2023 Mar; 40(3):1187-1203. PubMed ID: 36652175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mobocertinib: Mechanism of action, clinical, and translational science.
    Hanley MJ; Camidge DR; Fram RJ; Gupta N
    Clin Transl Sci; 2024 Mar; 17(3):e13766. PubMed ID: 38511563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy.
    Minchom A; Viteri S; Bazhenova L; Gadgeel SM; Ou SI; Trigo J; Bauml JM; Backenroth D; Bhattacharya A; Li T; Mahadevia P; Girard N
    Lung Cancer; 2022 Jun; 168():74-82. PubMed ID: 35597172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Indirect comparison of mobocertinib and real-world therapies for pre-treated non-small cell lung cancer with EGFR exon 20 insertion mutations.
    Christopoulos P; Prawitz T; Hong JL; Lin HM; Hernandez L; Jin S; Tan M; Proskorovsky I; Lin J; Zhang P; Patel JD; Ou SI; Thomas M; Stenzinger A
    Lung Cancer; 2023 May; 179():107191. PubMed ID: 37058788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer
    Kim TM; Girard N; Low GKM; Zhuo J; Yu DY; Yang Y; Murota M; Lim CTK; Kleinman NJ; Cho BC
    Acta Oncol; 2023 Dec; 62(12):1689-1697. PubMed ID: 37938161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial.
    Zhou C; Ramalingam SS; Kim TM; Kim SW; Yang JC; Riely GJ; Mekhail T; Nguyen D; Garcia Campelo MR; Felip E; Vincent S; Jin S; Griffin C; Bunn V; Lin J; Lin HM; Mehta M; Jänne PA
    JAMA Oncol; 2021 Dec; 7(12):e214761. PubMed ID: 34647988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting EGFR Exon 20 Insertion Mutation in Non-small cell Lung Cancer: Amivantamab and Mobocertinib.
    Russell MC; Garelli AM; Reeves DJ
    Ann Pharmacother; 2023 Feb; 57(2):198-206. PubMed ID: 35652704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.
    Passaro A; Wang J; Wang Y; Lee SH; Melosky B; Shih JY; Wang J; Azuma K; Juan-Vidal O; Cobo M; Felip E; Girard N; Cortot AB; Califano R; Cappuzzo F; Owen S; Popat S; Tan JL; Salinas J; Tomasini P; Gentzler RD; William WN; Reckamp KL; Takahashi T; Ganguly S; Kowalski DM; Bearz A; MacKean M; Barala P; Bourla AB; Girvin A; Greger J; Millington D; Withelder M; Xie J; Sun T; Shah S; Diorio B; Knoblauch RE; Bauml JM; Campelo RG; Cho BC;
    Ann Oncol; 2024 Jan; 35(1):77-90. PubMed ID: 37879444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The budget impact of introducing mobocertinib for the postplatinum treatment of advanced non-small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutations.
    Hernandez L; Young M
    J Manag Care Spec Pharm; 2023 Feb; 29(2):172-186. PubMed ID: 36373869
    [No Abstract]   [Full Text] [Related]  

  • 13. Amivantamab plus Chemotherapy in NSCLC with
    Zhou C; Tang KJ; Cho BC; Liu B; Paz-Ares L; Cheng S; Kitazono S; Thiagarajan M; Goldman JW; Sabari JK; Sanborn RE; Mansfield AS; Hung JY; Boyer M; Popat S; Mourão Dias J; Felip E; Majem M; Gumus M; Kim SW; Ono A; Xie J; Bhattacharya A; Agrawal T; Shreeve SM; Knoblauch RE; Park K; Girard N;
    N Engl J Med; 2023 Nov; 389(22):2039-2051. PubMed ID: 37870976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer.
    Cho BC; Felip E; Hayashi H; Thomas M; Lu S; Besse B; Sun T; Martinez M; Sethi SN; Shreeve SM; Spira AI
    Future Oncol; 2022 Feb; 18(6):639-647. PubMed ID: 34911336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with
    Riely GJ; Neal JW; Camidge DR; Spira AI; Piotrowska Z; Costa DB; Tsao AS; Patel JD; Gadgeel SM; Bazhenova L; Zhu VW; West HL; Mekhail T; Gentzler RD; Nguyen D; Vincent S; Zhang S; Lin J; Bunn V; Jin S; Li S; Jänne PA
    Cancer Discov; 2021 Jul; 11(7):1688-1699. PubMed ID: 33632775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC.
    Wang K; Du R; Myall NJ; Lewis WE; Uy N; Hong L; Skoulidis F; Byers LA; Tsao A; Cascone T; Pozadzides J; Tu J; Negrao MV; Gibbons DL; Park K; Rinsurongkawong W; Lee JJ; Gandara D; Behl D; Shu CA; Riess JW; Baik C; Wakelee HA; Vaporciyan AA; Heymach JV; Zhang J; Le X
    J Thorac Oncol; 2024 Mar; 19(3):500-506. PubMed ID: 38012986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis.
    Illini O; Saalfeld FC; Christopoulos P; Duruisseaux M; Vikström A; Peled N; Demedts I; Dudnik E; Eisert A; Hashemi SMS; Janzic U; Kian W; Mohorcic K; Mohammed S; Silvoniemi M; Rothschild SI; Schulz C; Wesseler C; Addeo A; Armster K; Itchins M; Ivanović M; Kauffmann-Guerrero D; Koivunen J; Kuon J; Pavlakis N; Piet B; Sebastian M; Velthaus-Rusik JL; Wannesson L; Wiesweg M; Wurm R; Albers-Leischner C; Aust DE; Janning M; Fabikan H; Herold S; Klimova A; Loges S; Sharapova Y; Schütz M; Weinlinger C; Valipour A; Overbeck TR; Griesinger F; Jakopovic M; Hochmair MJ; Wermke M
    Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New therapies in non-small cell lung cancer with EGFR exon 20 insertion mutations.
    David GM; Maria Del Pilar BC; Cristina MR
    J Oncol Pharm Pract; 2023 Jun; 29(4):934-943. PubMed ID: 36916182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Validation of Companion Diagnostics for the Selection of Patients with Non-Small Cell Lung Cancer Tumors Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutations for Treatment with Amivantamab.
    Jatkoe T; Wang S; Odegaard JI; Velasco Roth AM; Osgood D; Martinez G; Lucas P; Curtin JC; Karkera J
    J Mol Diagn; 2022 Nov; 24(11):1181-1188. PubMed ID: 35963523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation.
    Odogwu L; Mathieu L; Goldberg KB; Blumenthal GM; Larkins E; Fiero MH; Rodriguez L; Bijwaard K; Lee EY; Philip R; Fan I; Donoghue M; Keegan P; McKee A; Pazdur R
    Oncologist; 2018 Mar; 23(3):353-359. PubMed ID: 29242281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.